J&J Medical Connect
UPTRAVI®

(selexipag)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

UPTRAVI® (selexipag)
Medical Information

UPTRAVI - Alternative Dosing and Titration Schedule

Last Updated: 11/04/2026

SUMMARY

  • In the pivotal phase 3 study, GRIPHON (Prostacyclin [PGI2] Receptor agonist In Pulmonary arterial HypertensiON), UPTRAVI was initiated at 200 mcg twice daily (BID) and increased weekly in increments of 200 mcg BID, as tolerated, up to a maximum dose of 1600 mcg BID.1
  • SPHERE (SelexiPag: tHe usErs dRug rEgistry) registry study showed that the median maintenance dose of UPTRAVI was 1100 mcg BID in 729 of 759 patients with pulmonary arterial hypertension (PAH). In the overall PAH population (n=759), the median duration of UPTRAVI titration was 8.1 weeks, with 671 (88.4%) patients titrating at speeds slower than 200 mcg BID per week and 88 (11.6%) patients titrating at speeds equal to or faster than 200 mcg BID per week; 97 (12.8%) patients received a different or an unrecorded UPTRAVI dose, the specific outcomes of which are not available.2,3
  • EXPOSURE (EXPloratory Observational Study of Uptravi in Real-lifE) is an ongoing, Europe and Canada-based, multicenter, prospective, observational study of PAH patients initiating PAH-specific therapy. Three dose groups were defined (low, medium, and high) in the study based on patients’ individualized dose (ID) at the end of titration. Overall, 6% (n=36) of patients received doses outside of the defined groups, for reasons that were not captured in EXPOSURE.4,5
  • An analysis of pooled data from the SPHERE and EXPOSURE studies reported that of the patients with PAH initiating UPTRAVI (N=894), 67.1% initiated it as a part of triple combination therapy. Additionally, of the 742 (83.0%) patients who had completed titration, the ID was reached in a median period of 8 weeks, with the median dose being 800 mcg BID.6
  • A retrospective study evaluated the efficacy and safety of UPTRAVI as a part of sequential triple combination therapy in patients with PAH (N=127). The maximally tolerated UPTRAVI doses were 1600 mcg BID, 1400 mcg BID, 1200 mcg BID, and ≤1000 mcg BID in 18.1%, 6.3%, 11%, and 64.6% of patients, respectively.7
  • A real-world, retrospective, observational cohort study evaluating adult patient outcomes across UPTRAVI dose ranges in the United States (US) using the Komodo closed-claims database reported the UPTRAVI dosage adjustments in varied patterns, across all the ID strata. Increase in maintenance dose by ≥200 mcg occurred ≥1 time in 112 (67.1%) patients in the low-ID group, 91 (48.1%) in the medium-ID group, and 75 (27.0%) in the high-ID group (standardized mean difference [SMD], 0.69). Decrease in the maintenance dose by ≥200 mcg occurred ≥1 time in 93 (55.7%) patients in the low-ID group, 79 (41.8%) in the medium-ID group, and 58 (20.9%) in the high-ID group (SMD, 0.46).8
  • A retrospective study examining real-world dosing patterns of UPTRAVI, and the effect of prior prostacyclin pathway agent (PPA) use on UPTRAVI dosing and discontinuation reported that the mean time to reach the individualized maintenance dose was 14 weeks (greater than that specified in the protocol outlined in the GRIPHON study [12 weeks]). The median time to reach the individualized maintenance dose was 56 days in the ≤weekly cohort and 86 days in the >weekly cohort.9
  • Another retrospective study examining real-world dosing patterns of UPTRAVI reported that the overall median time to reach the maintenance dose was 83 days, suggesting that clinicians may be titrating UPTRAVI slower than on a weekly basis.10
  • Additional studies are included in the REFERENCES section for your review.11-16
  • Administration of doses not specified in the UPTRAVI product label is not recommended.

CLINICAL DATA

GRIPHON Study

In the pivotal phase 3 study, GRIPHON, UPTRAVI was initiated at 200 mcg BID and increased weekly in increments of 200 mcg BID, as tolerated, up to a maximum dose of 1600 mcg BID. This dose adjustment phase spanned the first 12 weeks of treatment. To determine the highest tolerable dose, the dose was reduced by 200 mcg BID when an intolerable dose was reached.1

Alternative Dosing and Titration Schedule

SPHERE Registry

SPHERE (SelexiPag: tHe usErs dRug rEgistry) is a US-based, multicenter, prospective, observational, real-world registry. Adult patients (≥18 years of age) receiving UPTRAVI in routine clinical practice were enrolled from November 2016 to March 2020 and followed for up to 18 months. The study provided data on the realworld outcomes of UPTRAVI treatment in the US along with information regarding patient demographics and disease characteristics in the enrolled population.2

Of the total 829 patients with pulmonary hypertension (PH; World Health Organization [WHO] group I-V) enrolled in SPHERE, 759 had PAH (WHO group I), of whom 387 and 372 were newly (starting UPTRAVI ≤60 days before enrollment) and previously (starting UPTRAVI >60 days before enrollment) initiated on UPTRAVI, respectively.2

In 729 of 759 patients, the median maintenance dose of UPTRAVI was 1100 mcg BID (range, 100-3200 mcg). In the overall PAH population (n=759), the median duration of UPTRAVI titration was 8.1 weeks (range, 1.1-26.9 weeks), with 671 (88.4%) patients (newly initiated, n=338 [87.3%]; previously initiated, n=333 [89.5%]) titrating at speeds slower than 200 mcg BID per week and 88 (11.6%) patients (newly initiated, n=49 [12.7%]; previously initiated, n=39 [10.5%]) titrating at speeds equal to or faster than 200 mcg BID per week. One hundred and fourteen (15.0%), 238 (31.4%), and 310 (40.8%) patients received a BID maintenance dose of UPTRAVI 200-400 mcg, 6001000 mcg, and >1200 mcg, respectively, whereas 97 (12.8%) patients received a different or an unrecorded UPTRAVI dose, the specific outcomes of which are not available.2,3

Four-Strata Risk Assessment of EXPOSURE Study

EXPOSURE (EXPloratory Observational Study of Uptravi in Real-lifE) is an ongoing, Europe and Canada-based, multicenter, prospective, observational study of PAH patients initiating PAH-specific therapy. Adult patients with Group I PH initiating a new PAH-specific therapy within 1 month of or at enrollment were enrolled from September 2017 to November 2022 and followed for up to 3 years. This study provided data on real-world characteristics, treatment patterns, and outcomes of patients with PAH, categorized by risk status when initiated with UPTRAVI.4

Of the 698 patients enrolled with PAH, 163 did not have sufficient data to allow for risk evaluation, leaving 535 patients for baseline risk assessment calculations. Patients with available baseline data were grouped into low (n=76), intermediate-low (n=168), intermediate-high (n=182), or high risk (n=109) of 1-year mortality according to the European Society of Cardiology and the European Respiratory Society (ESC/ERS) 4-strata method.4,5

There were 3 defined dose groups based on patients’ ID at the end of titration: low (200 or 400 mcg BID), medium (600, 800 or 1000 mcg BID), and high dose (1200, 1400, or 1600 mcg BID). A total of 36 patients received doses outside of the defined dose groups for reasons not captured in EXPOSURE: 9 patients in the low risk group received alternative doses (50 mcg [n=1], 300 mcg [n=5], 500 mcg [n=2], and 2000 mcg [n=1] BID); 6 in the intermediate-low risk group (300 mcg [n=3] and 700 mcg [n=3] BID); 7 in the intermediate-high risk group (300 mcg [n=1], 500 mcg [n=2], 700 mcg [n=3], and 1500 mcg [n=1] BID); 4 in the high risk group (100 mcg [n=2], 300 mcg [n=1], and 700 mcg [n=1] BID). Overall, patients received 50 mcg (n=1), 100 mcg (n=5), 300 mcg (n=12), 500 mcg (n=6), 700 mcg (n=9), 900 mcg (n=1), 1500 mcg (n=1), and 2000 mcg (n=1) BID.4,5

An analysis based on pooled data from the SPHERE and EXPOSURE studies assessed treatment patterns in patients with PAH newly initiating UPTRAVI (N=894; SPHERE, n=389; EXPOSURE, n=505). Overall, the proportion of patients who initiated UPTRAVI as part of double- and triple-treatment therapy was 20.9% and 67.1%, respectively. Additionally, 16.8% of patients initiated UPTRAVI within 6 months of PAH diagnosis. At data cutoff, dose titration was completed in 742 (83.0%) patients within a median (quartile [Q]1-Q3) period of 8 (4-12.5) weeks. The median (Q1-Q3) ID in these patients was 800 (400-1400) µg BID.6

Overall, the median (Q1-Q3) UPTRAVI exposure was 10.8 (3.3-18.6) months. At 1 year, the proportion of patients who were free from all-cause hospitalization in the low, intermediate-low, intermediate-high, and high-risk groups was 86%, 73%, 57%, and 45%, respectively. Among the patients with available risk scores, the corresponding Kaplan-Meier survival estimates were 100%, 96%, 91%, and 59%, respectively.6

UPTRAVI was discontinued by 388 (43.4%) patients, with the most common reasons for discontinuation being tolerability (n=173; 19.4%) and death (n=69, 7.7%). Additionally, the most common adverse events (AEs) leading to UPTRAVI discontinuation were headache (n=35, 3.9%), diarrhea (n=26, 2.9%), nausea (n=20, 2.2%), and myalgia (n=14, 1.6%).6

Alternative Dosing Schedule

Real-World Evidence

Tokgöz et al (2026)7 conducted a retrospective analysis to evaluate the efficacy and safety of UPTRAVI as a part of sequential triple combination therapy in patients with PAH. A total of 127 patients were included in the study, of whom 84.3% were female. The median (interquartile range [IQR]) follow-up period was 682 (224-985) days. The maximally tolerated UPTRAVI doses were 1600 mcg BID, 1400 mcg BID, 1200 mcg BID, and ≤1000 mcg BID in 18.1%, 6.3%, 11%, and 64.6% of patients, respectively. The patients were categorized as low-dose (200-400 mcg), medium-dose (600-1000 mcg), and high-dose (1200-1600 mcg) in 26%, 38.6%, and 35.4% of cases, respectively.

The 12-month and 36-month survival outcomes are summarized in the Table: Survival Outcomes


Survival Outcomes7
Group
12-month survival (%)
95% CI
36-month survival (%)
95% CI
Low-dose cohort (200-400 mcg)
89.8
79.3-100
72.5
52.6-100
Medium-dose cohort (600-1000 mcg)
95.3
89.1-100
85.7
74.6-98.4
High-dose cohort (1200-1600 mcg)
95.0
88.5-100
75.1
61.2-92.2
Abbreviation: CI, confidence interval.

UPTRAVI discontinuation due to AEs was reported in 19 (15%) patients. The most common AEs were headache; pain in the jaw, muscles, or legs; diarrhea, nausea, vomiting; and flushing. Clinical worsening and all-cause mortality were reported in 29 (22.8%) and 19 (15.1%) patients, respectively. Of the 19 patients who discontinued UPTRAVI, 5 died during the follow-up period.7

Alternative Titration Schedule

Real-World Evidence

Burger et al (2024)8 conducted a real-world, retrospective, observational cohort study to evaluate patient outcomes across UPTRAVI dose ranges in the US using the Komodo closed-claims database between December 15, 2015, and June 30, 2022. Eligibility criteria included adult patients treated with UPTRAVI during the study period and had ≥1 inpatient or 2 outpatient records with an International Classification of Diseases, Ninth or Tenth Revision (ICD-9/ ICD-10) diagnosis code for PH (on separate days, with ≥1 PH diagnosis prior to UPTRAVI initiation). The index date was UPTRAVI ID date defined as receipt of the first maintenance UPTRAVI dose pack used for >60 consecutive days.

A total of 1186 eligible patients with PAH were included in the study, of whom 634 (53.5%) completed the titration phase and reached their UPTRAVI ID, and categorized into high- (43.8%), medium- (29.8%), and low- (26.3%) ID strata. Across all ID strata, adjustments in UPTRAVI dosing occurred in varied patterns. In the high-ID group, a higher proportion of patients remained at their initial ID with fewer dose adjustments over time compared with the low- and medium-ID groups. The UPTRAVI maintenance dose was adjusted in 121 (72.5%), 117 (61.9%), and 96 (34.5%) patients in the low-, medium-, and high-ID group patients, respectively (SMD, 0.63). An increase in the maintenance dose by ≥200 mcg occurred ≥1 time in 112 (67.1%) patients in the low-ID group, 91 (48.1%) patients in the medium-ID group, and 75 (27%) patients in the high-ID group (SMD, 0.69). A decrease in maintenance dose by ≥200 mcg occurred ≥1 time in 93 (55.7%) patients in the low-ID group, 79 (41.8%) patients in the medium-ID group, and 58 (20.9%) patients in the high-ID group (SMD, 0.46).8 The details on UPTRAVI dose adjustments are summarized in the Table: UPTRAVI Dose Adjustments - Overall and According to Initial ID Reached.


UPTRAVI Dose Adjustments - Overall and According to Initial ID Reached8
Parameter
All Patients Reaching UPTRAVI ID
(N=634)

Low ID (UPTRAVI 200-400 mcg BID)
(n=167)

Medium ID (UPTRAVI
600-1000 mcg
BID)
(n=189)

High ID
(UPTRAVI
1200-1600 mcg
BID)
(n=278)

SMDa
Number of times maintenance dose was adjusted, n (%)
   None
300 (47.3)
46 (27.5)
72 (38.1)
182 (65.5)
0.63
   1
135 (21.3)
32 (19.2)
51 (27)
52 (18.7)
   ≥2
199 (31.4)
89 (53.3)
66 (34.9)
44 (15.8)
Number of times maintenance dose was increased by 200 mcg, n (%)
   None
514 (81.1)
119 (71.3)
133 (70.4)
262 (94.2)
0.46
   1
78 (12.3)
28 (16.8)
39 (20.6)
11 (4)
   ≥2
42 (6.6)
20 (12)
17 (9)
5 (1.8)
Number of times dose was decreased by 200 mcg, n (%)
   None
516 (81.4)
124 (74.3)
144 (76.2)
248 (89.2)
0.31
   1
83 (13.1)
26 (15.6)
30 (15.9)
27 (9.7)
   ≥2
35 (5.5)
17 (10.2)
15 (7.9)
3 (1.1)
Number of times dose was increased by ≥200 mcg, n (%)
   None
356 (56.2)
55 (32.9)
98 (51.9)
203 (73)
0.69
   1
157 (24.8)
43 (25.7)
55 (29.1)
59 (21.2)
   ≥2
121 (19.1)
69 (41.3)
36 (19.0)
16 (5.8)
Number of times dose was decreased by ≥200 mcg, n (%)
   None
404 (63.7)
74 (44.3)
110 (58.2)
220 (79.1)
0.46
   1
129 (20.3)
33 (19.8)
52 (27.5)
44 (15.8)
   ≥2
101 (15.9)
60 (35.9)
27 (14.3)
14 (5)
Abbreviations: BID, twice daily; ID, individualized dose; SMD, standardized mean difference.aSMD <0.1 predefined as indicating covariate balance between the cohorts.

Palevsky et al (2020)9 conducted a retrospective study using de-identified specialty pharmacy data from January 01, 2016 to March 29, 2019, to examine real-world dosing patterns of UPTRAVI and the effect of prior PPA use on UPTRAVI dosing and discontinuation. Adult patients (≥18 years old) who attained their individualized maintenance doses were included. These patients were further categorized into 2 cohorts (based on dosing pattern and PPA use), which each had 2 subcategories ([≤weekly cohort: patients who received titration ≤8 days/200 mcg BID; >weekly cohort: patients who received titration >8 days/200 mcg BID] and [prior-use cohort: patients with a history of PPA use; naïve cohort: patients without a history of PPA use]).

Of the 3931 patients who attained their individualized maintenance doses, 2869 (73%) were female, and the mean (±standard deviation [SD]) age was 57.9 (±14.8) years. The mean time to reach the individualized maintenance dose was 14 weeks (greater than that specified in the protocol outlined in the GRIPHON study [12 weeks]).

The ≤weekly and >weekly cohorts included 550 (14%) and 3381 (86%) patients, respectively. The median time to reach the individualized maintenance dose was 56 days in the ≤weekly cohort and 86 days in the >weekly cohort. The median time to reach the individualized maintenance dose for patients on low, medium, and high individualized maintenance doses were 73, 83, and 89 days, respectively. Results pertaining to patients with (n=523; 13.3%) and without (n=3408; 86.7%) a history of PPA use are presented in Table: Outcomes in Patients With and Without a History of PPA Use.


Outcomes in Patients With and Without a History of PPA Use9
Parameter
Prior-Use Cohorta
(n=523; 13.3%)
Naïve Cohortb
(n=3,408; 86.7%)
P-Valuec
Maximum dose achieved at first individualized maintenance dose (mcg BID), median
1600
1200
<0.001
Speed of titration, n (%)
   Patients who had ≤weekly titration (fast)
110 (21)
440 (12.9)
<0.001
   Patients who had >weekly titration (slow)
413 (79)
2968 (87.1)
<0.001
Abbreviations: BID, twice daily; PPA, prostacyclin pathway agent.
a
Prior-use cohort consists of patients with a history of PPA use. bNaïve cohort consists of patients without a history of PPA use. cP-Value <0.05 is considered significant.

The lack of information on whether PAH was incident or prevalent, the status of existing comorbidities, whether patients were on concomitant mediations, and if the medication was taken as prescribed was a set of limitations of this study. Additionally, the inability to identify if patients started the maintenance phase with a titration package and the context of treatment discontinuation were also noted as the study limitations.

Kung et al (2018)10 conducted a retrospective study using dosing and shipment records from specialty pharmacies to examine the real-world dosing patterns of UPTRAVI. Patients with ≥6 months of exposure to UPTRAVI and 6 shipments were included.

At the time of analysis, 2490 patients were exposed to UPTRAVI for ≥6 months and had corresponding shipment data. The overall median time to reach the maintenance dose was 83 days, suggesting that clinicians may be titrating UPTRAVI slower than on a weekly basis.

LiTERATURE Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) was conducted on 07 October 2026.

 

References

1 Sitbon O, Channick R, Chin K, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-2533.  
2 McLaughlin V, Farber HW, Highland KB, et al. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). J Heart Lung Transplant. 2024;43(2):272-283.  
3 McLaughlin V, Farber HW, Highland KB, et al. Supplement to: Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). J Heart Lung Transplant. 2024;43(2):272-283.  
4 Lange TJ, Escribano-Subias P, Muller A, et al. Four-strata risk assessment in patients with pulmonary arterial hypertension treated with selexipag in real-world settings (EXPOSURE study). Adv Ther. 2024;41(9):3645-3663.  
5 Lange TJ, Escribano-Subias P, Muller A, et al. Supplement to: Four-strata risk assessment in patients with pulmonary arterial hypertension treated with selexipag in real-world settings (EXPOSURE study). Adv Ther. 2024;41(9):3645-3663.  
6 Escribano Subias P, Chakinala MM, Chin KM, et al. Real-world experience with selexipag in patients with pulmonary arterial hypertension: treatment patterns and outcomes across baseline risk strata (SPHERE and EXPOSURE studies). Drugs Real World Outcomes. 2026;13(1):85-100.  
7 Tokgöz HC, Kaymaz C, Kültürsay B, et al. Could we maintain the initial efficacy of triple sequential combination therapies with selexipag against progressive deterioration risk in patients with pulmonary arterial hypertension: insights from a single-center study? Anatol J Cardiol. 2026;30(4):248-258.  
8 Burger CD, Tang W, Tsang Y, et al. Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension. Pulm Circ. 2024;14(3):e12415.  
9 Palevsky H, Pruett J, Ogbomo A, et al. Examining dosing patterns for selexipag in real-world practice using US specialty pharmacy data. Poster presented at: Academy of Managed Care Pharmacy (AMCP); April 21-24, 2020; Houston, TX.  
10 Kung T, Archer-Chicko C, Raspa S, et al. Dosing trends for UPTRAVI (selexipag) in real-world practice: a review of specialty pharmacy data. Abstract presented at: Annual Meeting of the American College of Chest Physicians (CHEST); October 6-10, 2018; San Antonio, TX.  
11 Bruderer S, Hurst N, Kaufmann P, et al. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014;94(3-4):148-156.  
12 Parikh K, Doerfler S, Shelburne N, et al. Experience in transitioning from parenteral prostacyclins to selexipag in pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2020;75(4):299-304.  
13 Verlinden N, Walter C, Kanwar M, et al. Transition from oral treprostinil to selexipag in a patient with pulmonary arterial hypertension. Ann Pharmacother. 2019;53(7):764-765.  
14 Morales-Estrella J, Chen A, Heresi G. Successful transition from oral selexipag to intravenous epoprostenol [abstract]. Am J Respir Crit Care Med. 2018;197:A3695.  
15 Habib N, Feldman J. Three-a-day dosing of selexipag in the treatment of pulmonary arterial hypertension: a case series [abstract]. Am J Respir Crit Care Med. 2018;197:Abstract A3719.  
16 Lange T, Escribano-Subias P, Borissoff J, et al. Real-world clinical outcomes according to individualised selexipag dose in pulmonary arterial hypertension (PAH). Abstract presented at: European Respiratory Society (ERS) Congress 2025; September 27-October 1, 2025; Amsterdam, Netherlands.  

Would you like to clear and leave your conversation? Message history will be lost.